A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer

Yonghong Li, PhD*, Andre R. Arellano, BS, Lance A. Bare, PhD, Richard A. Bender, MD, Charles M. Strom, MD, PhD, James J. Devlin, PhD

Quest Diagnostics, San Juan Capistrano, CA, USA

ABSTRACT

Background: The National Comprehensive Cancer Network recommends that women who carry gene variants that confer substantial risk for breast cancer consider risk-reduction strategies, that is, enhanced surveillance (breast magnetic resonance imaging and mammography) or prophylactic surgery. Pathogenic variants can be detected in women with a family history of breast or ovarian cancer syndromes by multigene panel testing. Pathogenic variants in breast cancer-associated genes explain approximately 15% of breast cancer deaths [1].

Women with a family history of breast cancer are at increased risk, with about 13% of women with breast cancer having one or more first-degree relatives with the disease [2]. Pathogenic variants in the BRCA1 and BRCA2 genes explain approximately 15% of the breast cancer familial relative risk (i.e., the ratio of the risk of an individual with an affected relative to the risk of individuals in the general population), whereas pathogenic variants in other genes, including TP53, PTEN, CDH1, and PALB2, contribute further to the familial relative risk for breast cancer [3].

Women with a pathogenic variant in BRCA1 have a 65% chance of developing breast cancer by age 70 years, whereas those with a BRCA2 pathogenic variant have a 45% chance [4]. In contrast, women in the general population have a 7% chance of developing breast cancer [1].

Methods: To investigate whether using a seven-gene test to identify women who should consider risk-reduction strategies could cost-effectively increase life expectancy.

Results: The incremental cost-effectiveness ratio for the seven-gene test strategy compared with the BRCA1/2 test strategy was $42,067 per life-year gained or $69,920 per quality-adjusted life-year gained for the 50-year-old cohort and $23,734 per life-year gained or $48,328 per quality-adjusted life-year gained for the 40-year-old cohort. In probabilistic sensitivity analysis, the seven-gene test strategy cost less than $100,000 per life-year gained in 95.7% of the trials for the 50-year-old cohort.


Keywords: BRCA, breast cancer, cost-effectiveness, multigene panel testing.

Copyright © 2017, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

Introduction

Breast cancer is the most commonly diagnosed noncutaneous cancer and the second leading cause of cancer death among women in the United States. An estimate for 2015 predicted 231,840 new cases of breast cancer and 40,290 breast cancer deaths [1]. Women with a family history of breast cancer are at increased risk, with about 13% of women with breast cancer having one or more first-degree relatives with the disease [2]. Pathogenic variants in the BRCA1 and BRCA2 genes explain approximately 15% of the breast cancer familial relative risk (i.e., the ratio of the risk of an individual with an affected relative to the risk of individuals in the general population), whereas pathogenic variants in other genes, including TP53, PTEN, CDH1, and PALB2, contribute further to the familial relative risk for breast cancer [3].

Women with a pathogenic variant in BRCA1 have a 65% chance of developing breast cancer by age 70 years, whereas those with a BRCA2 pathogenic variant have a 45% chance [4]. In contrast, women in the general population have a 7% chance of developing breast cancer [1]. Pathogenic variants in other breast cancer-associated genes can also confer substantial risk. For example, a recent study reported that women with a pathogenic variant in PALB2 have a 33% to 58% chance of developing breast cancer by age 70 years, a risk similar to that of women with a pathogenic variant in BRCA2 [5]. Pathogenic variants in breast cancer–associated genes also increase the risk of developing ovarian and other cancers [3].

For women whose lifetime risk of breast cancer is greater than 20%, the National Comprehensive Cancer Network (NCCN) guidelines recommend enhanced breast cancer surveillance by magnetic resonance imaging (MRI). The NCCN guidelines also recommend risk-reducing oophorectomy for BRCA1/2 carriers, and the NCCN Breast Cancer Risk Reduction Panel supports “the use of RRM [risk-reducing mastectomy] in carefully selected women at high risk for breast cancer who desire this intervention (e.g. women with a BRCA1/2, TP53, PTEN, CDH1 or STK11 mutation …)” [6]. These recommended procedures have been shown to confer substantial survival benefits on at-risk individuals [7–10]. For example, clinical studies have found that risk-reducing mastectomy can decrease the risk of developing breast cancer by more than 90% for women with a family history of breast cancer.
cancer or with a pathogenic variant in BRCA1 or BRCA2 [7–9]. And decision-analytic modeling has predicted that enhanced surveillance could increase life expectancy by 1.4 years for 50-year-old women who carry a pathogenic variant in BRCA1 and by 1.0 year if they carry a pathogenic variant in BRCA2 [10]. Similarly, risk-reducing mastectomy could increase life expectancy by 2.8 years for BRCA1 carriers and by 2.0 years for BRCA2 carriers; younger women would receive greater survival benefits [10].

Genetic analysis is recommended for individuals at risk of hereditary breast cancer [11,12]. Basic genetic testing for breast cancer detects pathogenic germline variants in the BRCA1 and BRCA2 genes, and the test results are used to guide the assessment and management of breast cancer risk. Newer testing options allow for the simultaneous analysis of expanded panels of genes, which include BRCA1/2 as well as other genes whose pathogenic variants confer moderate to high risk for breast cancer [13,14]. Recent clinical studies have found that testing with expanded gene panels identifies substantially more individuals with pathogenic variants in breast cancer–associated genes than does BRCA1/2 testing alone, and that the detection of these pathogenic variants in these genes can lead to clinical action [15,16].

For women at high risk of breast or ovarian cancer, BRCA1/2 testing followed by prophylactic surgery when test-positive has been found to be cost-effective compared with no BRCA1/2 testing [17–19]. This raises the question of whether testing with an expanded panel of breast cancer–associated genes is cost-effective compared with BRCA1/2 testing alone. In this study, we used a decision-analytic model to compare the relative cost and effectiveness of a seven-gene panel test strategy with a BRCA1/2 test strategy for women at risk of hereditary breast cancer.

**Methods**

**Model**

The objective of this study was to inform the risk-reduction decisions of women at risk of hereditary breast cancer by comparing the effectiveness and lifetime costs of the use of either BRCA1/2 testing or seven-gene testing from a payer perspective. To this end, a decision-analytic model with Markov nodes was developed for hypothetical cohorts of 50-year-old and 40-year-old asymptomatic women with a family history of breast or ovarian cancer or other hereditary syndromes such as Li-Fraumeni syndrome and Cowden syndrome that predispose to breast cancer (Fig. 1). The model compares two strategies for detecting pathogenic genetic variants and using the test results to select appropriate breast cancer risk reduction: the usual care strategy tests for variants in the BRCA1 and BRCA2 genes (BRCA1/2 testing) and the other strategy tests for variants in the BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, and PALB2 genes (seven-gene testing). Individuals who carry a pathogenic variant in any one of these genes are considered test-positive; otherwise, they are considered test-negative. Women who test positive were assumed to receive genetic counseling and recommendations to follow the NCCN breast cancer risk-reduction guidelines [11]. Specifically, women who test positive were assumed to undergo annual surveillance by mammography and MRI till age 75 years or immediately undergo prophylactic risk-reducing mastectomy. Individuals who test negative were assumed to undergo annual surveillance by mammography till age 75 years.

Patient outcomes were evaluated using a Markov model with a lifetime time horizon (lifetime limited to age 100 years) with a cycle length of 1 year (Fig. 1). The patients enter the model in the well state (i.e., no breast or ovarian cancer) and can remain in the well state, progress to breast or ovarian cancer, or die. Patients who survive breast or ovarian cancer for 5 years return to the well state and were assumed to have the same probability of developing breast or ovarian cancer (recurrent cancer rate) as did those in the well state who never had cancer. This recurrent cancer rate affects the model outcome only for the five-gene test-positive subgroup (groups that are BRCA1/2 test-positive or test-negative for all seven genes cancel out between the two strategies; see Fig. 1). This recurrent cancer rate is consistent with the rate (5%) reported by Bosco et al. [20] for the period between 5 and 10 years after breast cancer diagnosis, a rate that is on an annual basis similar to the base-case assumption (0.01196) for the five-gene test-positive group. The model does not allow patients to develop both breast and ovarian cancer because we assumed that this is a rare event. In health economics literature for breast cancer (e.g., [21]), co-occurrence of breast and ovarian cancer is often not included in the modeling. Other studies (e.g., [22]) considered that the risk of developing the two types of cancer is independent and consequently co-occurrence of breast and ovarian cancer is rare.

**Model Parameters**

Model parameters were based on peer-reviewed literature, Medicare fee schedules, and government agency program databases, as presented in Table 1 for the cohort of 50-year-old women. The frequencies of BRCA1 and BRCA2 carriers among the high-risk women were taken from a cross-sectional study of 46,276 women in the United States [23]; the seven-gene panel test (BRCAvantage Plus, Quest Diagnostics) and the BRCA1/2 test were assumed to have equal sensitivity and specificity for the detection of
دریافت فوری
متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات